Jane Kapustin
Adult Health · Clarksville, MDNPI 1114921681
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.1%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Sanofi-aventis U.S. LLC accounts for 63.1% of it on its own, with 30 other manufacturers making up the rest. Among adult health clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 327 payments — averaging $135.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$28K
- Cequr Corporation$5K
- Madrigal Pharmaceuticals$5K
- Novo Nordisk$1K
- Lilly USA, LLC$987
- AstraZeneca$874
- plus $4K from 25 others
What the payments were for
- Consulting fees$8,49019%
- Speaking & faculty fees$23,58753%
- Travel & lodging$1,5333%
- Food & beverage$10,66924%
- Education$760%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 77 | $28,040 |
| Cequr Corporation | 5 | $5,015 |
| Madrigal Pharmaceuticals | 12 | $4,751 |
| Novo Nordisk | 54 | $1,228 |
| Lilly USA, LLC | 45 | $987 |
| AstraZeneca | 30 | $874 |
| Acella Pharmaceuticals, LLC | 1 | $735 |
| Corcept Therapeutics | 19 | $726 |
| Xeris Pharmaceuticals, Inc. | 10 | $220 |
| Zealand Pharma US, Inc. | 5 | $181 |
| Boehringer Ingelheim | 8 | $173 |
| Tandem Diabetes Care, Inc. | 6 | $163 |
| Merck | 9 | $152 |
| Ascensia Diabetes Care US Inc. | 3 | $151 |
| Bayer | 7 | $134 |
| BETA Bionics, Inc. | 1 | $119 |
| Amarin Pharma, Inc. | 7 | $115 |
| Abbott | 6 | $110 |
| Mannkind Corporation | 3 | $96 |
| Dexcom, Inc. | 1 | $88 |
| Amgen | 3 | $58 |
| Medtronic | 2 | $52 |
| Ascendis Pharma Endocrinology Inc | 2 | $46 |
| Baxter Healthcare | 2 | $41 |
| Sequel Med Tech, LLC | 2 | $39 |
| Lifescan, Inc. | 2 | $32 |
| Antares Pharma, Inc. | 1 | $24 |
| Philips North America LLC | 1 | $19 |
| Globus Medical | 1 | $18 |
| Tolmar, Inc. | 1 | $15 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TZIELD$12,767
- SOLIQUA 100/33$6,513
- CeQur Simplicity$4,900
- REZDIFFRA$4,570
- NP Thyroid 60$735
- iLet Bionic Pancreas$357
- FARXIGA$326
- RYBELSUS$124
- iLet Insulin Infusion Kit Inset$119
- iLet Insulin Infusion Kit Contact Detach$119
- Ozempic$118
- TOUJEO$112
- Korlym$106
How this compares
$44,414 in reported general payments places this provider in the 95th percentile of 542 adult health providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 162 | $319,866 |
| FarxigaDapagliflozin Propanediol | 78 | $105,939 |
| Tresiba Flextouch U-200Insulin Degludec | 60 | $88,950 |
| MounjaroTirzepatide | 51 | $80,761 |
| TrulicityDulaglutide | 33 | $76,673 |
| JardianceEmpagliflozin | 46 | $58,196 |
| Xigduo XrDapaglifloz Propaned/Metformin | 24 | $37,230 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 14 | $22,122 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $19,720 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $19,536 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 11 | $18,652 |
| SynjardyEmpagliflozin/Metformin Hcl | 12 | $17,749 |
| Novolog FlexpenInsulin Aspart | 31 | $13,175 |
| JanuviaSitagliptin Phosphate | 12 | $10,715 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 52 | $7,760 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,228 | $319,866162 claims |
| Lilly USA, LLCMounjaro, Trulicity | $987 | $157,43584 claims |
| AstraZenecaFarxiga | $874 | $105,93978 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy | $173 | $98,06772 claims |
| MerckJanuvia | $152 | $10,71512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 542 adult health providers in Maryland.
Other adult health in Clarksville
- Lucia NovakCamp Springs$473K
- Caroline RuhlAnnapolis$315K
- Joyce MiskovicHighland$264K
- Christopher RobersonBaltimore$180K
- Amit DhirBaltimore$97K
- Morgan JoliatSykesville$92K
- Brendon BowerBaltimore$64K
- Caitlin NassBaltimore$46K
- Sarah RileyBaltimore$24K
- Hanieh KhorshidiPotomac$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.